Table of Contents Author Guidelines Submit a Manuscript

A corrigendum for this article has been published. To view the corrigendum, please click here.

Disease Markers
Volume 2016, Article ID 9214056, 14 pages
Review Article

Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications

1Medical Oncology Department, Hospital Universitario Doce de Octubre, 28041 Madrid, Spain
2Centro Nacional de Investigaciones Oncológicas (CNIO), 28029 Mardid, Spain

Received 31 March 2016; Revised 8 June 2016; Accepted 9 June 2016

Academic Editor: Monica Neagu

Copyright © 2016 A. Quintanal-Villalonga et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Lung cancer is a heterogeneous disease responsible for the most cases of cancer-related deaths. The majority of patients are clinically diagnosed at advanced stages, with a poor survival rate. For this reason, the identification of oncodrivers and novel biomarkers is decisive for the future clinical management of this pathology. The rise of high throughput technologies popularly referred to as “omics” has accelerated the discovery of new biomarkers and drivers for this pathology. Within them, tyrosine kinase receptors (TKRs) have proven to be of importance as diagnostic, prognostic, and predictive tools and, due to their molecular nature, as therapeutic targets. Along this review, the role of TKRs in the different lung cancer histologies, research on improvement of anti-TKR therapy, and the current approaches to manage anti-TKR resistance will be discussed.